Journal of Clinical Oncology - ASCO Publications
WEBSep 9, 2024 · A world where cancer is prevented or cured. Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. Through research, education, and promotion of the highest-quality, equitable patient care, ASCO works to conquer cancer and create a …
Management of Stage III Non–Small-Cell Lung Cancer: ASCO …
WEBDec 22, 2021 · PURPOSE To provide evidence-based recommendations to practicing clinicians on management of patients with stage III non–small-cell lung cancer (NSCLC). METHODS An Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary oncology, community oncology, research methodology, and advocacy experts was convened to conduct a literature search, which included systematic ...
Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline
WEBPURPOSE To provide guidance to clinicians regarding therapy for patients with brain metastases from solid tumors. METHODS ASCO convened an Expert Panel and conducted a systematic review of the literature. RESULTS Thirty-two randomized trials published in 2008 or later met eligibility criteria and form the primary evidentiary base. RECOMMENDATIONS Surgery is a reasonable option for patients ...
Management of Cancer Therapy–Associated Oral Mucositis
WEBFeb 3, 2020 · Mucositis is a common and feared complication of anticancer therapy that can affect up to 90% of certain populations of patients with cancer. Even seemingly uncomplicated mucositis, which is often self-limited, can result in intense patient discomfort and decline in quality of life. Severe mucositis can be complicated by uncontrolled pain, superinfection or systemic infection, bleeding, and ...
Management of Immune-Related Adverse Events in Patients …
WEBPURPOSE To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitor (ICPi) therapy. METHODS A multidisciplinary panel of medical oncology, dermatology, gastroenterology, rheumatology, pulmonology, endocrinology, neurology, hematology, emergency medicine, nursing ...
Evidence-Based Management of Oral Mucositis | JCO Oncology …
WEBFeb 3, 2020 · The morbidity of oral mucositis includes pain, nutritional compromise, and infection risk, which potentially result in breaks or dose reductions in cancer therapy. Historically, management was focused mainly on pain control and nutritional support. However, evidence-based clinical practice guidelines for …
ASCO Clinical Practice Guidelines | Journal of Clinical Oncology
WEBFor more information on these guidelines, including information about planned guidelines, please access the ASCO.org guidelines page. Clinical practice guidelines serve as a guide for doctors and outline appropriate methods of treatment and care. Guidelines can address specific clinical situations (disease-oriented) or use of approved medical ...
Current and Future Management of HER2-Positive Metastatic …
WEBHuman epidermal growth factor receptor 2 (HER2) is overexpressed and/or amplified in approximately 20% of breast cancers, conferring an aggressive tumor behavior but also an opportunity for targeted therapies. In the advanced setting, the prognosis of patients suffering from this disease has greatly improved after the introduction of new anti-HER2 drugs beyond trastuzumab. For most patients, a ...
When a Monoclonal Gammopathy Is Not Multiple Myeloma
WEBApr 8, 2022 · A monoclonal gammopathy is a laboratory-based finding that is being increasingly recognized in the aging population. Until recently, the incidence of monoclonal gammopathy of undetermined significance (MGUS) was based on studies from Olmsted County, Minnesota, and from Scandinavian health records, indicating an incidence of approximately 1%. 1 The majority of MGUS cases arise from a malignant ...
Antiemetics: ASCO Guideline Update | Journal of Clinical Oncology
WEBJul 13, 2020 · The first ASCO guideline for antiemetics was published in 1999, 1 with updates in 2006, 2 2011, 3 2015, 4 and 2017. 5 This update of the 2017 guideline provides guidance on the use of dexamethasone as a prophylactic antiemetic in patients receiving CPIs. This guideline update addresses programmed death-1 (PD-1), programmed death 1–ligand (PD ...